Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation
Chemical Biology & Drug Design · 2026-03 · 107 (3)
DOI: 10.1111/cbdd.70280 ↗At a glance
Journal article in Chemical Biology & Drug Design, published online on 2026-03-26. Written by Aisha A Alsfouk and 10 co-authors. Institution: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Major MEDLINE topics: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents, Thiadiazoles, Protein Kinase Inhibitors. Cited 2 times so far (Crossref); 74 references. Funded by: Princess Nourah Bint Abdulrahman University.
Abstract (original language)
In this study, a series of novel thiadiazole derivatives ( 7a , 7b , 9a , 9b , and 9c ) were rationally designed as potential VEGFR‐2 inhibitors using a pharmacophore‐guided strategy. The compounds were synthesized and assessed for their antiangiogenic and anticancer effects. Among them, compound 9b showed the strongest VEGFR‐2 inhibition (IC 50 = 0.030 ± 0.001 μM), outperforming the reference drug Sorafenib. Cytotoxicity tests revealed that 9b was highly effective against MCF‐7 breast cancer cells (IC 50 = 8.06 ± 0.7 μM) while exhibiting minimal toxicity toward normal WI‐38 cells. Flow cytometry demonstrated that 9b induced significant G2/M cell cycle arrest and increased apoptosis, supported by molecular data showing upregulation of caspase‐3 and Bax and downregulation of Bcl‐2, indicating activation of the intrinsic apoptotic pathway. Extensive in silico studies—including molecular docking, 200 ns molecular dynamics simulations, interaction mapping, principal component analysis of trajectories, and free energy landscape analysis—confirmed that 9b binds stably and efficiently within the VEGFR‐2 active site. Overall, these results highlight compound 9b as a promising VEGFR‐2‐targeted antiangiogenic agent with potent enzymatic and cellular activity, favorable selectivity, and mechanistic validation through combined experimental and computational approaches.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Department of Chemistry, Faculty of Science, Al-Azhar University, Cairo, Egypt.
- Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
ORCID profiles: Aisha A Alsfouk, Hazem Elkady, Walid E Elgammal, Hazem A Mahdy, Ibrahim H Eissa, Ahmed M Metwaly
Funding
- Princess Nourah Bint Abdulrahman University
Cite
APA
Alsfouk, A. A., Elkaeed, E. B., Elkady, H., Elgammal, W. E., Mahdy, H. A., Nofal, A., Eissa, I. H., Husein, D. Z., Ibrahim, I. M., Elkotamy, M. S., & Metwaly, A. M. (2026). Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation. Chemical Biology & Drug Design, 107(3). https://doi.org/10.1111/cbdd.70280
Vancouver
Alsfouk AA, Elkaeed EB, Elkady H, Elgammal WE, Mahdy HA, Nofal A, et al. Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation. Chemical Biology & Drug Design. 2026;107(3). doi:10.1111/cbdd.70280
BibTeX
@article{Alsfouk2026,
author = {Alsfouk, Aisha A and Elkaeed, Eslam B and Elkady, Hazem and Elgammal, Walid E and Mahdy, Hazem A and Nofal, Ahmed and Eissa, Ibrahim H and Husein, Dalal Z and Ibrahim, Ibrahim M and Elkotamy, Mahmoud S and Metwaly, Ahmed M},
title = {Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {3},
doi = {10.1111/cbdd.70280}
}
EUVIMED